Marriott (MAR) Declares $0.41 Quarterly Dividend; 1.4% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Marriott International (MAR) PT Lowered to $123 at Morgan Stanley
November 8, 2018 8:10 AM ESTMorgan Stanley analyst Thomas Allen lowered the price target on Marriott International (NASDAQ: MAR) to $123.00 (from $138.00) while maintaining a Equalweight rating.
... MoreMarriott International (MAR) PT Lowered to $123 at Deutsche Bank
November 7, 2018 5:22 AM ESTDeutsche Bank analyst Carlo Santarelli lowered the price target on Marriott International (NASDAQ: MAR) to $123.00 (from $136.00) while maintaining a Hold rating.
... MoreMarriott International (MAR) PT Lowered to $147 at Longbow Research
November 6, 2018 11:53 AM ESTLongbow Research analyst Alton Stump lowered the price target on Marriott International (NASDAQ: MAR) to $147.00 (from $156.00) while maintaining a Buy rating.
The cut following the EPS beat but disappointing Q3 RevPar.
... MorePre-Open Movers 11/06: (VCEL) (ELF) (MYL) Higher; (ONCS) (FTDR) (RL) Lower (more...)
November 6, 2018 9:24 AM ESTToday's Pre-Open Stock Movers
OncoSec Medical Incorporated (NASDAQ: ONCS) 56.9% LOWER; reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO (tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® (pembrolizumab) in patients with unresectable, advanced melanoma. Eligible patients had refractory, locally advanced or metastatic disease defined as unresectable Stage... More
